>>Description of the research protocol "20160250"

A multicenter, open-label, single-arm, extension study to assess long term safety of evolocumab therapy in subjects with clinically evident cardiovascular disease in selected european countries.
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Cardiologie
Brugmann identifier : 20160250
EudraCT identifier : 2016-004066-26
ClinicalTrials.gov identifier : NCT03080935


Involved department : Cardiology
Principal investigator : Catez
Sponsor : Amgen
Contact : Clinical Research Unit

>This protocol was approved by the CHU Liège ethics committee.